Bayer and Evotec Update Focus of their Collaboration to Cardiovascular Diseases
Strategic Alliance will Leverage Human iPSC Disease Modelling for Identification of Novel Targets
Berlin and Hamburg, Germany, 30 April 2024 – Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). [Read more…]